Novavax Inc NVAX shares are trading lower in Monday's after-hours session after the company reported worse-than-expected financial results.
Novavax reported first-quarter revenue of $704 million, which came in below the $845.2 million estimate, according to data from Benzinga Pro. The company reported quarterly earnings of $2.56 per share, which came in below the estimate of $2.69 per share.
Novavax said the first quarter was its first profitable quarter as a commercial-stage company. The company reiterated full-year 2022 revenue guidance of $4 billion to $5 billion.
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
NVAX 52-Week Range: $42.13 - $277.79
The stock was down 7.06% in after-hours at $49.50 at press time.
Photo: Maryland GovPics from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
